87
Participants
Start Date
April 24, 2020
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2025
VV1
VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
Cemiplimab
Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
WITHDRAWN
UPMC, Pittsburgh
WITHDRAWN
Georgetown University Medical Center, Washington D.C.
WITHDRAWN
Mayo Clinical, Jacksonville
COMPLETED
University of Miami, Miami
WITHDRAWN
Ohio State University, Columbus
RECRUITING
University of Cincinnati Medical Center, Cincinnati
WITHDRAWN
Masonic Cancer Center, University of Minnesota, Minneapolis
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Sanford Cancer Center, Sioux Falls
TERMINATED
Billings Clinic Montana Cancer Consortium, Billings
RECRUITING
Ochsner Clinic Foundation, New Orleans
WITHDRAWN
UT Health San Antonio MD Anderson Cancer Center, San Antonio
WITHDRAWN
Mayo Clinical, Phoenix
WITHDRAWN
USC Norris Comprehensive Cancer Center, Los Angeles
TERMINATED
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica
WITHDRAWN
City of Hope Medical Center, Durate
WITHDRAWN
HOAG Memorial Hospital Presbyterian, Newport Beach
WITHDRAWN
Stanford Health Care, Stanford
RECRUITING
Yale University, New Haven
WITHDRAWN
Massachusetts General Hospital Cancer Center, Boston
WITHDRAWN
Atlantic Health, Morristown
WITHDRAWN
Rutgers Cancer Institute of New Jersey, New Brunswick
RECRUITING
Hospital Sao Rafael, Salvador
RECRUITING
INCA, Rio de Janeiro
RECRUITING
Hospital Moinhos de Vento, Porto Alegre
ACTIVE_NOT_RECRUITING
Hospital de Amor de Barretos, Barretos
Regeneron Pharmaceuticals
INDUSTRY
Vyriad, Inc.
INDUSTRY